Next Article in Journal
Onychomycosis in Northwestern Greece over a 7-Year Period
Previous Article in Journal
Sequencing of Historical Isolates, K-mer Mining and High Serological Cross-Reactivity with Ross River Virus Argue against the Presence of Getah Virus in Australia
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Section
Special Issue
Volume
Issue
Number
Page
 
Logical OperatorOperator
Search Text
Search Type
 
add_circle_outline
remove_circle_outline
 
Open AccessReview

Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease

by 1, 2,3,* and 1,*
1
Department of Biotechnology, Thapar Institute of Engineering & Technology, Patiala 147004, Punjab, India
2
Department of Microbiology and Immunology, University of Nevada, Reno, NV 89557, USA
3
Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Tatarstan, Russia
*
Authors to whom correspondence should be addressed.
Pathogens 2020, 9(10), 850;
Received: 20 September 2020 / Revised: 7 October 2020 / Accepted: 16 October 2020 / Published: 17 October 2020
(This article belongs to the Special Issue Pathogenesis of Emerging Zoonotic Viral Infections)
Ebolaviruses, discovered in 1976, belongs to the Filoviridae family, which also includes Marburg and Lloviu viruses. They are negative-stranded RNA viruses with six known species identified to date. Ebola virus (EBOV) is a member of Zaire ebolavirus species and can cause the Ebola virus disease (EVD), an emerging zoonotic disease that results in homeostatic imbalance and multi-organ failure. There are three EBOV outbreaks documented in the last six years resulting in significant morbidity (>32,000 cases) and mortality (>13,500 deaths). The potential factors contributing to the high infectivity of this virus include multiple entry mechanisms, susceptibility of the host cells, employment of multiple immune evasion mechanisms and rapid person-to-person transmission. EBOV infection leads to cytokine storm, disseminated intravascular coagulation, host T cell apoptosis as well as cell mediated and humoral immune response. In this review, a concise recap of cell types targeted by EBOV and EVD symptoms followed by detailed run-through of host innate and adaptive immune responses, virus-driven regulation and their combined effects contributing to the disease pathogenesis has been presented. At last, the vaccine and drug development initiatives as well as challenges related to the management of infection have been discussed. View Full-Text
Keywords: T-cell immunity; bystander apoptosis; cytokines response; host immune evasion; Ebola vaccines T-cell immunity; bystander apoptosis; cytokines response; host immune evasion; Ebola vaccines
Show Figures

Figure 1

MDPI and ACS Style

Jain, S.; Khaiboullina, S.F.; Baranwal, M. Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. Pathogens 2020, 9, 850.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop